TY - JOUR
T1 - Hybrid strategy with a bioresorbable scaffold and a drug-coated balloon for diffuse coronary artery disease
T2 - The "no more metallic cages" multicentre pilot experience
AU - Ielasi, Alfonso
AU - Miyazaki, Tadashi
AU - Geraci, Salvatore
AU - Testa, Luca
AU - Abdel-Wahab, Mohamed
AU - Kawamoto, Hiroyoshi
AU - Ruparelia, Neil
AU - Sato, Takao
AU - Caramanno, Giuseppe
AU - Bedogni, Francesco
AU - Tespili, Maurizio
AU - Colombo, Antonio
AU - Latib, Azeem
PY - 2016/4/1
Y1 - 2016/4/1
N2 - Aims: Our aim was to assess the feasibility and results of a hybrid approach with a bioresorbable scaffold (BRS) plus a drug-coated balloon (DCB) for the treatment of diffuse coronary artery disease (CAD). Methods and results: A retrospective analysis was performed on consecutive patients with diffuse de novo or in-stent restenosis treated with BRS implantation (larger proximal segment) and DCB inflation (smaller distal segment or bifurcation side branch). Endpoints were procedural success, then ischaemia-driven target lesion revascularisation (ID-TLR) and BRS/DCB segment thrombosis rates at follow-up. A total of 42 consecutive patients were treated with the hybrid strategy. Mean patient age was 62±1.02 years, while 12 (28.6%) patients were diabetics. Mean BRS and DCB length were 28.0±5.1 mm and 25.8±8.8 mm, respectively. Procedural success was obtained in all patients, but three (7.3%) patients required bail-out scaffolding for DCB-related dissection. At a median follow-up of 12 months (IQR: 6-18), there were no cases of cardiac death, target vessel myocardial infarction, or BRS/DCB segment thrombosis. ID-TLR occurred in two (4.7%) BRS-treated segments. Conclusions: Our data in consecutive patients with diffuse CAD suggest that a hybrid strategy using BRS and DCB in different segments of the diseased vessel is feasible and associated with encouraging clinical outcomes.
AB - Aims: Our aim was to assess the feasibility and results of a hybrid approach with a bioresorbable scaffold (BRS) plus a drug-coated balloon (DCB) for the treatment of diffuse coronary artery disease (CAD). Methods and results: A retrospective analysis was performed on consecutive patients with diffuse de novo or in-stent restenosis treated with BRS implantation (larger proximal segment) and DCB inflation (smaller distal segment or bifurcation side branch). Endpoints were procedural success, then ischaemia-driven target lesion revascularisation (ID-TLR) and BRS/DCB segment thrombosis rates at follow-up. A total of 42 consecutive patients were treated with the hybrid strategy. Mean patient age was 62±1.02 years, while 12 (28.6%) patients were diabetics. Mean BRS and DCB length were 28.0±5.1 mm and 25.8±8.8 mm, respectively. Procedural success was obtained in all patients, but three (7.3%) patients required bail-out scaffolding for DCB-related dissection. At a median follow-up of 12 months (IQR: 6-18), there were no cases of cardiac death, target vessel myocardial infarction, or BRS/DCB segment thrombosis. ID-TLR occurred in two (4.7%) BRS-treated segments. Conclusions: Our data in consecutive patients with diffuse CAD suggest that a hybrid strategy using BRS and DCB in different segments of the diseased vessel is feasible and associated with encouraging clinical outcomes.
KW - Angioplasty
KW - Bioresorbable scaffold
KW - Diffuse coronary artery disease
KW - Drug-coated balloon
KW - Outcomes
UR - http://www.scopus.com/inward/record.url?scp=84981718128&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84981718128&partnerID=8YFLogxK
U2 - 10.4244/EIJV11I14A309
DO - 10.4244/EIJV11I14A309
M3 - Article
VL - 11
SP - e1589-e1595
JO - EuroIntervention
JF - EuroIntervention
SN - 1774-024X
IS - 14
ER -